Journal: Breast cancer research : BCR
Article Title: Transcriptomic analysis identifies enrichment of cAMP/PKA/CREB signaling in invasive lobular breast cancer.
doi: 10.1186/s13058-024-01900-y
Figure Lengend Snippet: Fig. 5 A Dose response curves representing growth inhibition in ILC (red: SUM44PE, MM134, MM330, WCRC25, MM453, HCC2185) and NST (blue: MCF7, T47D, MM415, BT474) cell lines in response to treatment with forskolin: Y axis represents fold change in growth after 7 days of treatment with forskolin and X axis represents log of dose of forskolin in µM B Overlapping box and jitter plot depicting IC50 (half maximal inhibitory concentration) for forskolin in ILC (red: SUM44PE, MM134, MM330, WCRC25, MM453, HCC2185) and NST (blue: MCF7, T47D, MM415, BT474) cell lines; C ILC—Invasive lobular breast cancer; NST—Invasive carcinoma—no special type; PKACA—Protein kinase A catalytic α subunit; CREB—cAMP Response Element Binding protein; p-CREB—phospho CREB, phosphorylated at Ser133; Ecad KO—E-cadherin Knock Out; IC50—Half maximal inhibitory concentration
Article Snippet: Primary antibody incubation was performed overnight at 4 °C: P-CREB (Ser133) (87G3) (Cell Signaling Technology #9198; 10 ug/ml), PKA-Cα (Cell Signaling Technology #4782; 1:100).
Techniques: Inhibition, Concentration Assay, Binding Assay, Knock-Out